Extracranial oligometastatic renal cell carcinoma: Current management and future directions

Future Oncology

Volumn 10, Issue 5, 2014, Pages 761-774

  Loh, Jasmin ^a   Davis, Ian D ^b   Martin, Jarad M ^a   Siva, Shankar ^c,d  

^a NEWCASTLE MATER HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

immunotherapy; metastasectomy; oligometastases; renal cell carcinoma; stereotactic ablative body radiation therapy; targeted therapy

Indexed keywords

AGS 003; ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; BMS 936559; EVEROLIMUS; INTERLEUKIN 2; IPILIMUMAB; MDX 1105; MPDL 3280A; NIVOLUMAB; PAZOPANIB; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROTEIN ANTIBODY; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TICILIMUMAB; UNCLASSIFIED DRUG;

ABLATION THERAPY; BONE METASTASECTOMY; BONE METASTASIS; CANCER SURVIVAL; EXTRACRANIAL OLIGOMETASTATIC RENAL CELL CARCINOMA; HUMAN; IMAGING; IMMUNOTHERAPY; KIDNEY METASTASIS; LIVER METASTASIS; LOCAL THERAPY; LUNG METASTASIS; MELANOMA; METASTASIS RESECTION; NEPHRECTOMY; NONHUMAN; PANCREAS METASTASIS; PATIENT SELECTION; PRIORITY JOURNAL; PULMONARY METASTASECTOMY; REVIEW; STEREOTACTIC ABLATIVE BODY RADIATION THERAPY; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMIC THERAPY; THYROID METASTASIS; UNSPECIFIED SIDE EFFECT; CARCINOMA, RENAL CELL; HEALTH CARE QUALITY; METASTASIS; PATHOLOGY; PROGNOSIS; RADIOSURGERY;

CARCINOMA, RENAL CELL; HUMANS; NEOPLASM METASTASIS; PROGNOSIS; RADIOSURGERY; STANDARD OF CARE;

EID: 84899866463     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.40     Document Type: Review

References (96)

1. Hellman S, Weichselbaum RR. Oligometastases. J. Clin. Oncol. 13(1), 8-10 (1995).
2. Macdermed DM, Weichselbaum RR, Salama JK. A rationale for the targeted treatment of oligometastases with radiotherapy. J. Surg. Oncol. 98(3), 202-206 (2008).
3. Weickhardt AJ, Scheier B, Burke JM et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J. Thorac. Oncol. 7(12), 1807-1814 (2012).
4. Christodouleas JP, Marks LB. Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses: in regard to Milano et al. (Int J Radiat Oncol Biol Phys 2009;73: 832-837). Int. J. Radiat. Oncol. Biol. Phys. 74(5), 1628; author reply 1628-1629 (2009).
5. Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J. Clin. Oncol. 40(2), 107-111 (2010).
6. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med. 335(12), 865-875 (1996).
7. Goetz P, Ebinu JO, Roberge D, Zadeh G. Current standards in the management of cerebral metastases. Int. J. Surg. Oncol. 2012, 493426 (2012).
8. Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 12(7), 884-898 (2007).
9. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8(2), 98-101 (1989).
10. Sluka P, Davis ID. Cell mates: paracrine and stromal targets for prostate cancer therapy. Nat. Rev. Urol. 10(8), 441-451 (2013).
11. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 127(4), 679-695 (2006).
12. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883-892 (2012).
13. Kosari F, Parker AS, Kube DM et al. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin. Cancer Res. 11(14), 5128-5139 (2005).
14. Wuttig D, Baier B, Fuessel S et al. Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. Int. J. Cancer 125(2), 474-482 (2009).
15. Lussier YA, Xing HR, Salama JK et al. MicroRNA expression characterizes oligometastasis(es). PLoS ONE 6(12), e28650 (2011).
16. Sohaib SA, Cook G, Allen SD, Hughes M, Eisen T, Gore M. Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer. Br. J. Radiol. 82(980), 632-639 (2009).
17. Lawrentschuk N, Davis ID, Bolton DM, Scott AM. Functional imaging of renal cell carcinoma. Nat. Rev. Urol. 7(5), 258-266 (2010).
18. Oosterwijk-Wakka JC, Boerman OC, Mulders PF, Oosterwijk E. Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int. J. Mol. Sci. 14(6), 11402-11423 (2013).
19. Barney JJ. A twelve-year cure following nephrectomy for adenocarcinoma and lobectomy for solitary metastasis. Trans. Am. Assoc. Genitourin. Surg. 37, 189-191 (1945).
20. Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann. Thorac. Surg. 74(5), 1653-1657 (2002).
21. Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur. Urol. 48(1), 77-81; discussion 81-72 (2005).
22. Meimarakis G, Angele M, Staehler M et al. Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. Am. J. Surg. 202(2), 158-167 (2011).
23. Murthy SC, Kim K, Rice TW et al. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann. Thorac. Surg. 79(3), 996-1003 (2005).
24. Assouad J, Petkova B, Berna P, Dujon A, Foucault C, Riquet M. Renal cell carcinoma lung metastases surgery: pathologic findings and prognostic factors. Ann. Thorac. Surg. 84(4), 1114-1120 (2007).
25. Baloch KG, Grimer RJ, Carter SR, Tillman RM. Radical surgery for the solitary bony metastasis from renal-cell carcinoma. J. Bone Joint Surg. Br. 82(1), 62-67 (2000).
26. Fuchs B, Trousdale RT, Rock MG. Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment. Clin. Orthop. Relat. Res. (431), 187-192 (2005).
27. Jung ST, Ghert MA, Harrelson JM, Scully SP. Treatment of osseous metastases in patients with renal cell carcinoma. Clin. Orthop. Relat. Res. (409), 223-231 (2003).
28. Lin PP, Mirza AN, Lewis VO et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J. Bone Joint Surg. Am. 89(8), 1794-1801 (2007).
29. Szendroi A, Dinya E, Kardos M et al. Prognostic factors and survival of renal clear cell carcinoma patients with bone metastases. Pathol. Oncol. Res. 16(1), 29-38 (2010).
30. Kozlowski JM. Management of distant solitary recurrence in the patient with renal cancer. Contralateral kidney and other sites. Urol. Clin. North Am. 21(4), 601-624 (1994).
31. Iesalnieks I, Winter H, Bareck E et al. Thyroid metastases of renal cell carcinoma: clinical course in 45 patients undergoing surgery. Assessment of factors affecting patients' survival. Thyroid 18(6), 615-624 (2008).
32. Staehler MD, Kruse J, Haseke N et al. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J. Urol. 28(4), 543-547 (2010).
33. Aloia TA, Adam R, Azoulay D, Bismuth H, Castaing D. Outcome following hepatic resection of metastatic renal tumors: the Paul Brousse Hospital experience. HPB (Oxford) 8(2), 100-105 (2006).
34. Thelen A, Jonas S, Benckert C et al. Liver resection for metastases from renal cell carcinoma. World J. Surg. 31(4), 802-807 (2007).
35. Zerbi A, Ortolano E, Balzano G, Borri A, Beneduce AA, Di Carlo V. Pancreatic metastasis from renal cell carcinoma: which patients benefit from surgical resection? Ann. Surg. Oncol. 15(4), 1161-1168 (2008).
36. Reddy S, Wolfgang CL. The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol. 10(3), 287-293 (2009).
37. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117(13), 2873-2882 (2011).
38. Siva S, Macmanus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J. Thorac. Oncol. 5(7), 1091-1099 (2010).
39. Ning S, Trisler K, Wessels BW, Knox SJ. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80(12 Suppl.), 2519-2528 (1997).
40. Ranck MC, Golden DW, Corbin KS et al. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am. J. Clin. Oncol. 36(6), 589-595 (2013).
41. Zelefsky MJ, Greco C, Motzer R et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 82(5), 1744-1748 (2012).
42. Svedman C, Sandstrom P, Pisa P et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 45(7), 870-875 (2006).
43. Wersall PJ, Blomgren H, Lax I et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother. Oncol. 77(1), 88-95 (2005).
44. Teh B, Bloch C, Galli-Guevara M et al. The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomed. Imaging Interv. J. 3(1), e6 (2007).
45. Gilson B LG, Qian G, Fastaia M, Cangiane L. Hypo-fractionated stereotactic extra-cranial radiosurgery (hfsr) for primary and metastatic renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 66, S349-S349 (2006).
46. Balagamwala EH, Angelov L, Koyfman SA et al. Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma. J. Neurosurg. Spine 17(6), 556-564 (2012).
47. Nguyen QN, Shiu AS, Rhines LD et al. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 76(4), 1185-1192 (2010).
48. Gerszten PC, Burton SA, Ozhasoglu C et al. Stereotactic radiosurgery for spinal metastases from renal cell carcinoma. J. Neurosurg. Spine 3(4), 288-295 (2005).
49. Salama JK, Hasselle MD, Chmura SJ et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 118(11), 2962-2970 (2012).
50. Beitler JJ, Makara D, Silverman P, Lederman G. Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am. J. Clin. Oncol. 27(6), 646-648 (2004).
51. Siva S, Pham D, Gill S, Corcoran NM, Foroudi F. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int. 110(11 Pt B), e737-e743 (2012).
52. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007).
53. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 28(6), 1061-1068 (2010).
54. Motzer RJ, Hutson TE, Cella D et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 369(8), 722-731 (2013).
55. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007).
56. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet 370(9605), 2103-2111 (2007).
57. Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28(13), 2137-2143 (2010).
58. Escudier B, Szczylik C, Hutson TE et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(8), 1280-1289 (2009).
59. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372(9637), 449-456 (2008).
60. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised Phase 3 trial. Lancet 378(9807), 1931-1939 (2011).
61. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007).
62. Motzer RJ, Nosov D, Eisen T et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a Phase III trial. J. Clin. Oncol. 31(30), 3791-3799 (2013).
63. Mickisch GH, Garin A, Van Poppel H et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286), 966-970 (2001).
64. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345(23), 1655-1659 (2001).
65. Choueiri TK, Xie W, Kollmannsberger C et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J. Urol. 185(1), 60-66 (2011).
66. Warren M, Venner PM, North S et al. A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can. Urol. Assoc. J. 3(4), 281-289 (2009).
67. Barbastefano J, Garcia JA, Elson P et al. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int. 106(9), 1266-1269 (2010).
68. ClinicalTrials.gov. Randomized Phase III Trial Evaluating The Importance Of Nephrectomy In Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib. http://clinicaltrials.gov/show/NCT00930033
69. ClinicalTrials.gov. Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma. http://clinicaltrials.gov/show/NCT01099423
70. Johannsen M, Staehler M, Ohlmann CH et al. Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. Ann. Oncol. 22(3), 657-663 (2011).
71. Chapin BF, Delacroix SE Jr, Culp SH et al. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur. Urol. 60(5), 964-971 (2011).
72. Powles T, Kayani I, Blank C et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann. Oncol. 22(5), 1041-1047 (2011).
73. Karam JA, Rini BI, Varella L et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J. Urol. 185(2), 439-444 (2011).
74. Tong CC, Ko EC, Sung MW et al. Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS ONE 7(6), e36979 (2012).
75. Bockorny B, Dasanu CA. Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches. Expert Opin Biol. Ther. 13(6), 911-925 (2013).
76. Postow MA, Callahan MK, Barker CA et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366(10), 925-931 (2012).
77. Siva S, Macmanus MP, Martin RF, Martin OA. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett. doi:10.1016/j.canlet.2013.09.018 (2013) (Epub ahead of print).).
78. Siva S, Callahan J, Macmanus MP, Martin O, Hicks RJ, Ball DL. Abscopal [corrected] effects after conventional and stereotactic lung irradiation of non-small-cell lung cancer. J. Thorac. Oncol. 8(8), e71-e72 (2013).
79. Wersall PJ, Blomgren H, Pisa P, Lax I, Kalkner KM, Svedman C. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol. 45(4), 493-497 (2006).
80. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J. Natl Cancer Inst. 105(4), 256-265 (2013).
81. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12(1), 991-1045 (1994).
82. Matzinger P. The danger model: a renewed sense of self. Science 296(5566), 301 (2002).
83. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-? production within the tumor microenvironment influences antitumor immunity. J. Immunol. 180(5), 3132-3139 (2008).
84. Lee Y, Auh SL, Wang Y et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114(3), 589-595 (2009).
85. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat. Rev. Clin. Oncol. 11(1), 24-37 (2013).
86. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012).
87. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
88. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122-133 (2013).
89. Weber JS, Kudchadkar RR, Yu B et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J. Clin. Oncol. 31(34), 4311-4318 (2013).
90. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369(2), 134-144 (2013).
91. ClinicalTrials.gov. A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy. http://clinicaltrials.gov/show/NCT01668784
92. Yang JC, Hughes M, Kammula U et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30(8), 825-830 (2007).
93. Ozao-Choy J, Ma G, Kao J et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69(6), 2514-2522 (2009).
94. ClinicalTrials.gov. A Phase 1 Study of Nivolumab (BMS-936558) Plus Sunitinib, Pazopanib or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma. http://clinicaltrials.gov/show/NCT01472081
95. Seung SK, Curti BD, Crittenden M et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2-tumor and immunological responses. Sci. Transl. Med. 4(137), 137ra174 (2012).
96. Masucci GV, Wersall P, Kiessling R, Lundqvist A, Lewensohn R. Stereotactic ablative radio therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours. J. Transl. Med. 10, 104 (2012).